Olema Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Amounts in thousands, except for share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $33,720 | $68,539 |
| Marketable securities | 215,257 | 193,268 |
| Prepaid expenses and other current assets | 3,113 | 4,706 |
| Total current assets | 252,090 | 266,513 |
| Operating lease right-of-use assets | 2,055 | 2,291 |
| Other assets and long-term deposits | 9,549 | 8,141 |
| Total assets | $263,694 | $276,945 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $7,656 | $2,698 |
| Operating lease liabilities, current | 1,057 | 988 |
| Other current liabilities | 17,511 | 17,935 |
| Total current liabilities | 26,224 | 21,621 |
| Operating lease liabilities, net of current portion | 1,152 | 1,429 |
| Total liabilities | 27,376 | 23,050 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value; 490,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 55,932,127 and 55,097,118 shares issued as of March 31, 2024 and December 31, 2023, respectively; 55,867,863 and 54,992,784 shares outstanding as of March 31, 2024 and December 31, 2023, respectively. | 4 | 4 |
| Additional paid-in capital | 572,926 | 559,176 |
| Accumulated other comprehensive (loss) income | (10) | 347 |
| Accumulated deficit | (336,602) | (305,632) |
| Total stockholders’ equity | 236,318 | 253,895 |
| Total liabilities and stockholders’ equity | $263,694 | $276,945 |
Condensed Consolidated Statements of Operations and Comprehensive Loss
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.